中药抗丙肝颗粒联合派罗欣加利巴韦林治疗慢性丙型肝炎的临床观察

《中药抗丙肝颗粒联合派罗欣加利巴韦林治疗慢性丙型肝炎的临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、提要目的：通过临床观察，研究探讨中药抗丙肝颗粒联合“长效干扰素+利巴韦林”治疗慢性丙型肝炎的临床疗效。方法：选择符合纳入标准的慢性丙型肝炎患者60例，随机分为两组，对照组（30例）给予皮下注射长效干扰素并口服利巴韦林，试验组（30例）在对照组用药基础上加用中药抗丙肝颗粒，两组均以24周为疗程，观察比较两组的疗效差异。结果：临床研究显示，试验组临床综合疗效、中医证候疗效均优于对照组（P<0.05或P<0.01），试验组能明显改善患者血清ALT、AST等生化指标，其疗效优于对照组（P<0.05或P<0.01），两组治疗期间均未发生严重不良反应。结论：中药抗丙肝颗

2、粒联合“长效干扰素+利巴韦林”是治疗慢性丙型肝炎的有效方案，中药抗丙肝颗粒可有效的减轻患者症状，改善患者肝功能，本研究肯定了其疗效。关键词中药抗丙肝颗粒；长效干扰素；慢性丙型肝炎；临床研究Anti-HCVParticlesCombinedwithPegylatedInterferonplusribavirininthetreatmentofchronichepatitiscurativeeffectobservationSpecialty：InternalMedicineofTCM.Author:：SunYanfenTutor：ProfessorZhangY

3、ongAbstractObjective:Throughclinicalobservation,researchoftraditionalChinesemedicineantiHCVparticleswithpegylatedinterferonplusribavirinforchronichepatitisCclinicalcurativeeffect.Methods:ClinicalselectionmettheinclusioncriteriaforchronichepatitisCin60cases,wererandomlydividedintotw

4、ogroups,theexperimentalgroup(n=30)givenmedicineagainsthepatitisCparticleswithlong-actinginterferonincombinationwithribavirin,acontrolgroup(n=30)givenalong-actinginterferonincombinationwithribavirin,twogroupstake48weeksforthedurationoftreatment,theclinicaleffectswerecomparedbetweent

5、hetwogroups.Results:Clinicalstudieshaveshown,theexperimentalgrouptheeffectofTCMWMTreatment,symptomswerebetterthanthecontrolgroup(P<0.05orP<0.01)theexperimentalgroupcansignificantlyimprovepatientswithliverfunction,viralloadtestingindex,itseffectisbetterthanthatofcontrolgroup(P<0.05o

6、rP<0.01)twogroupsduringtreatmentshowednoadversereaction.Conclusions:TraditionalChinesemedicineagainstHCVparticleswithlong-actinginterferonincombinationwithribavirinisthetreatmentofchronichepatitisCandeffectiveprescriptions,thisstudyaffirmsitsefficacy.KeyWordsAnti-HCVparticles；pegyl

7、atedinterferon；ChronichepatitisC；Clinicalstudy目录引言...............................................................................................................................1资料与方法...................................................................................................

8、........................2一